Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Donald W. Mann is active.

Publication


Featured researches published by Donald W. Mann.


Bioorganic & Medicinal Chemistry Letters | 2008

Comparative structure–activity relationship studies of 1-(5-methylsulfonylpyrid-2-yl)-5-alkyl and (hetero)aryl triazoles and pyrazoles in canine COX inhibition

Subas M. Sakya; Andrei Shavnya; Hengmiao Cheng; Chao Li; Bryson Rast; Jin Li; David A. Koss; Burton H. Jaynes; Donald W. Mann; Carol F. Petras; Scott B. Seibel; Michelle L. Haven; Michael P. Lynch

Structure-activity relationship (SAR) studies of novel 5-alkyl and 5-aryl/heteroaryl substituted 1,2,4-triazoles are described. The in vitro activity is compared to the pyrazole class of compounds with analogous side chains to delineate the contribution of the triazole ring nitrogen in binding to the active site. Both series are quite potent and selective in the canine whole blood (CWB) COX-2 assay, suggesting the increased binding contribution of the hydrophobic side chains.


Epilepsia | 2014

Safety, tolerability, and pharmacokinetics of pregabalin in children with refractory partial seizures: A phase 1, randomized controlled study

Donald W. Mann; Jing Liu; Marci L. Chew; Howard N. Bockbrader; Christine Alvey; Elizabeth Zegarac; John M. Pellock; Verne Pitman

To evaluate the safety, tolerability, and pharmacokinetics (PK) of pregabalin as adjunctive therapy in children with refractory partial seizures.


Bioorganic & Medicinal Chemistry Letters | 2006

5-Heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part 1: Structure-activity relationship studies of 5-alkylamino pyrazoles and discovery of a potent, selective, and orally active analog

Subas M. Sakya; Kristin Lundy DeMello; Martha L. Minich; Bryson Rast; Andrei Shavnya; Robert J. Rafka; David A. Koss; Hengmiao Cheng; Jin Li; Burton H. Jaynes; Carl Bernard Ziegler; Donald W. Mann; Carol F. Petras; Scott B. Seibel; Annette M. Silvia; David M. George; Lisa A. Lund; Suzanne H. St. Denis; Anne Hickman; Michelle L. Haven; Michael P. Lynch


Bioorganic & Medicinal Chemistry Letters | 2006

Synthesis and SAR of heteroaryl-phenyl-substituted pyrazole derivatives as highly selective and potent canine COX-2 inhibitors.

Hengmiao Cheng; Kristin Lundy DeMello; Jin Li; Subas M. Sakya; Kazuo Ando; Kiyoshi Kawamura; Tomoki Kato; Robert J. Rafka; Burton H. Jaynes; Carl Bernard Ziegler; Rod Stevens; Lisa A. Lund; Donald W. Mann; Carolyn Rose Kilroy; Michelle L. Haven; Erik L. Nimz; Jason K. Dutra; Chao Li; Martha L. Minich; Nicole L. Kolosko; Carol F. Petras; Annette M. Silvia; Scott B. Seibel


Bioorganic & Medicinal Chemistry Letters | 2004

Discovery of a potent, selective and orally active canine COX-2 inhibitor, 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl-pyridine.

Jin Li; Kristin Lundy DeMello; Henry Cheng; Subas M. Sakya; Brian Scott Bronk; Robert J. Rafka; Burton H. Jaynes; Carl Bernard Ziegler; Carolyn Rose Kilroy; Donald W. Mann; Eric L. Nimz; Michael P. Lynch; Michelle L. Haven; Nicole L. Kolosko; Martha L. Minich; Chao Li; Jason K. Dutra; Bryson Rast; Rhonda Marie Crosson; Barry James Morton; Glen W. Kirk; Kathleen M. Callaghan; David A. Koss; Andrei Shavnya; Lisa A. Lund; Scott B. Seibel; Carol F. Petras; Annette M. Silvia


Bioorganic & Medicinal Chemistry Letters | 2007

5-Heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part III: Molecular modeling studies on binding contribution of 1 -(5 -methylsulfonyl )pyrid -2 -yl and 4-nitrile

Subas M. Sakya; Xinjun Hou; Martha L. Minich; Bryson Rast; Andrei Shavnya; Kristin Lundy DeMello; Hengmiao Cheng; Jin Li; Burton H. Jaynes; Donald W. Mann; Carol F. Petras; Scott B. Seibel; Michelle L. Haven


Bioorganic & Medicinal Chemistry Letters | 2006

5-Heteroatom-substituted pyrazoles as canine COX-2 inhibitors: Part 2. Structure–activity relationship studies of 5-alkylethers and 5-thioethers

Subas M. Sakya; Hengmiao Cheng; Kristin Lundy DeMello; Andrei Shavnya; Martha L. Minich; Bryson Rast; Jason K. Dutra; Chao Li; Robert J. Rafka; David A. Koss; Jin Li; Burton H. Jaynes; Carl Bernard Ziegler; Donald W. Mann; Carol F. Petras; Scott B. Seibel; Annette M. Silvia; David M. George; Anne Hickman; Michelle L. Haven; Michael P. Lynch


Bioorganic & Medicinal Chemistry | 2005

In vitro and in vivo profile of 2-(3-di-fluoromethyl-5-phenylpyrazol-1-yl)-5-methanesulfonylpyridine, a potent, selective, and orally active canine COX-2 inhibitor

Jin Li; Michael P. Lynch; Kristin Lundy DeMello; Subas M. Sakya; Hengmiao Cheng; Robert J. Rafka; Brian Scott Bronk; Burton H. Jaynes; Carolyn Rose Kilroy; Donald W. Mann; Michelle L. Haven; Nicole L. Kolosko; Carol F. Petras; Scott B. Seibel; Lisa A. Lund


Archive | 1997

2-Aminobenzazapine derivatives

Christopher B. Cooper; Joseph P. Lyssikatos; Donald W. Mann; Scott J. Hecker


Archive | 1997

2-Aminobenzazepine derivatives and their use for the treatment of immunosuppression

Christopher B. Cooper; Scott J. Hecker; Joseph P. Lyssikatos; Donald W. Mann

Collaboration


Dive into the Donald W. Mann's collaboration.

Researchain Logo
Decentralizing Knowledge